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Abstract
Background: Carbonaceous nanoparticles possess an emerging source of human exposure due
to the massive release of combustion products and the ongoing revolution in nanotechnology.
Pulmonary inflammation caused by deposited nanoparticles is central for their adverse health
effects. Epidemiological studies suggest that individuals with favourable lung physiology are at lower
risk for particulate matter associated respiratory diseases probably due to efficient control of
inflammation and repair process. Therefore we selected a mouse strain C3H/HeJ (C3) with robust
lung physiology and exposed it to moderately toxic carbon nanoparticles (CNP) to study the
elicited pulmonary inflammation and its resolution.
Methods: 5 μg, 20 μg and 50 μg CNP were intratracheally (i.t.) instilled in C3 mice to identify the
optimal dose for subsequent time course studies. Pulmonary inflammation was assessed using
histology, bronchoalveolar lavage (BAL) analysis and by a panel of 62 protein markers.
Results: 1 day after instillation of CNP, C3 mice exhibited a typical dose response, with the lowest
dose (5 μg) representing the 'no effect level' as reflected by polymorphonuclear leucocyte (PMN),
and BAL/lung concentrations of pro-inflammatory proteins. Histological analysis and BAL-protein
concentration did not reveal any evidence of tissue injury in 20 μg CNP instilled animals.
Accordingly time course assessment of the inflammatory response was performed after 3 and 7
days with this dose (20 μg). Compared to day 1, BAL PMN counts were significantly decreased at
day 3 and completely returned to normal by day 7. We have identified protein markers related to
the acute response and also to the time dependent response in lung and BAL. After complete
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resolution of PMN influx on day 7, we detected elevated concentrations of 20 markers that
included IL1B, IL18, FGF2, EDN1, and VEGF in lung and/or BAL. Biological pathway analysis
revealed these factors to be involved in a closely regulated molecular cascade with IL1B/IL18 as
upstream and FGF2/EDN1/VEGF as downstream molecules.
Conclusion:  Considering the role of VEGF, FGF2 and EDN1 in lung development and
morphogenesis together with the lack of any evident tissue damage we suggest a protective/
homeostatic machinery to be associated in lungs of stable organisms to counter the CNP challenge
as a precautionary measure.
Introduction
Various epidemiological and clinical studies have shown
the correlation between ambient air particle concentra-
tion and adverse respiratory health effects throughout the
industrialized world [1-3]. It is considered that individu-
als with impaired lung physiology are at higher risk to var-
ious respiratory diseases like chronic obstructive
pulmonary disease (COPD) which are accelerated due to
chronic exposure to environmental stressors like ultrafine
particles/nano particles [4-6]. Therefore, individuals hav-
ing a favorable lung physiology are considered to be at
lower risk to various obstructive lung diseases probably
due to efficient control of inflammatory and/repair proc-
esses. In addition to the widely accepted adverse health
effects of anthropogenic airborne particulate pollution,
the increasing use of engineered nanopaticles in all
spheres of life has also become a new source of human
exposure [7]. Carbon nanoparticles (CNP) regardless of
their different sources, as combustion-derived nanoparti-
cles or carbon based engineered nanoparticles, are of tox-
icological interest given their nanosized dimensions, with
properties not displayed by their macroscopic counter-
parts. The pulmonary deposition efficiency of inhaled
sub-100 nm particles, along with their large surface areas,
is considered to be important in driving the emerging
health effects linked to respiratory toxicity [8,9].
To approach these issues experimentally we applied a
standardized exposure scenario to C3H/HeJ (C3) mice
with favorable lung physiology among several inbred
mouse strains and defined it as our physiological base
[10,11]. Moderately toxic and physically-chemically well
characterized carbon nanoparticles (CNP) [12] were used
as the exposure material and defined it as the toxicological
base. Carbon black is an ingredient in rubber, plastics,
inks and paints with an annual production of 10 million
tones [13] indicating its wide usage and potentially mas-
sive exposure in day to day life among people of various
working class. CNP also constitutes the core of combus-
tion derived particles [14] and represents relevant surro-
gates for exhaust particles from modern diesel engines
[15,16]. Since particle surface area and chemical composi-
tion have been described to drive particle related toxicity
[12,17,18] it is important to perform experiments with
well characterized particles like the here used CNP so as to
minimize the effects of uncharacterized chemical compo-
sition. CNP constitutes of 98% pure carbon [19] and
therefore exhibit no evidence for any bioactivation of
organic compounds. Hence the inflammatory efficacy of
CNP exclusively depends on their innate surface reactivity
[15].
A single exposure to ultrafine carbon black particles (here
called CNP) has been shown to cause a dose dependent
but transient inflammatory and cytotoxic response in the
lungs of rodents [20,21]. The goal of the present study is
to directly focus on this transient nature of the inflamma-
tory response by using the two defined bases (physiologi-
cal and toxicological) and analyze the time course
response following CNP exposure in lung tissue using a
comprehensive panel of well characterized protein mark-
ers. At this point our first aim was to characterize and
determinate the acute dose response to assess the validity
the applied protein markers and to identify the most suit-
able CNP dose to be used for the subsequent time course
analysis. Since previous experiments indicated that the
inflammatory response is to the greatest extent resolved at
day 7 after exposure, we limited our analysis to day 3 and
7. Response to foreign material deposited on the cellular
surface of the lungs due to particle inhalation is multidi-
mensional and includes the 'innate immune response',
the 'adaptive response' and the 'tissue repair and remode-
ling mechanism'. The central feature of the innate
immune response is the recruitment and activation of
granulocytes also called polymorphonuclear leucocytes
(PMN) at the site of stimulus [22], carbon nanoparticles
(CNP) in this case. The innate response is typically trig-
gered when pathogens like microbes are identified by pat-
tern recognition receptors, or when damaged, injured or
stressed cells send out alarm signals. Innate response
involves neutrophil, granulocytes, macrophages, platelets
and the complement system, but also eosinophils, mast
cells, basophils, and natural killer cells [23]. The adaptive/
specific immunity uses antigen specific receptors on the T
and B cells to drive targeted effector responses. The adap-
tive immunity involves the two way process of differenti-
ation and activation with the main modulators being
lymphocytes, alveolar macrophages and epithelial/Particle and Fibre Toxicology 2009, 6:31 http://www.particleandfibretoxicology.com/content/6/1/31
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endothelial cells [23]. The tissue response/repair and
remodeling mechanism involves the interaction of vari-
ous growth factors and fibroblasts to restore homeostasis
[24].
To investigate the complex response due to CNP exposure
standard procedures of cell differential counting and pro-
tein estimation from bronchoalveolar lavage (BAL) com-
bined with lung histology has been used to assess the
degree of inflammation. To gain insight into the underly-
ing molecular mechanism we applied a wide panel of 62
protein markers covering a broad spectrum of biological
processes (Additional file 1; Table S1), considered to be
important in relation to particle exposure. Our panel of
markers are known to play important roles in the follow-
ing key processes of lung tissue: i) Initiation and amplifi-
cation of inflammation ii)  Induction of T-cell
independent macrophage activation iii)  Regulation of
dendritic cell maturation and differentiation, and iv) Reg-
ulation of T-cell activation and differentiation as
described by [24]. The highlight of our work has been the
identification of protein markers for acute-dose and time-
course response following CNP exposure. We were able to
associate a closely orchestrated pathway with IL1B/IL18 as
the upstream and FGF2/EDN1/VEGF as the downstream
molecules thatis active even after the complete resolution
of PMN influx. Considering the role of VEGF, FGF2 and
EDN1 in lung development and morphogenesis together
with the lack of any evident tissue damage we suggest a
protective/homeostatic machinery to be activated in lungs
of stable organisms to counter the CNP challenge as a pre-
cautionary measure.
Results
The experimental animal groups were designed so as to
obtain an acute dose-response relationship [5 μg/day 1,
20 μg/day 1 and 50 μg/day 1] after CNP instillation and a
subsequent time course response for the moderate dose of
20 μg [20 μg/day 1, 20 μg/day 3, 20 μg/day 7] in C3 mice
following intra tracheal (i.t) instillation of CNP. Because
no significant differences where observed between
untreated controls and sham (vehicle) exposed controls
all CNP exposed groups were compared to sham exposed
controls.
BAL cell differentials and protein leakage
A dose dependent increase of PMN was detected on day 1
after CNP instillation in BAL samples of C3 mice. No sig-
nificant induction of PMN has been observed following
i.t. instillation of 5 μg CNP (9.41 ± 3.16 × 10E3 PMNs)
compared to the control (9.23 ± 3.05 × 10E3 PMNs). A
significant influx of PMN has been detected following 20
μg (105.53 ± 12.37 × 10E3 PMNs) and 50 μg (358.24 ±
41.91 × 10E3 PMNs) CNP instillation in a dose depend-
ent manner (Figure: 1a). BAL samples of 20 μg CNP
instilled lungs revealed significantly reduced PMN counts
after 3 days (25.78 ± 4.96 × 10E3 PMNs) and 7 days (2.54
± 0.57 × 10E3 PMNs) compared to that of day 1. At day 7
the PMN count reached to the baseline values indicating
complete resolution of the neutrophil influx related
inflammation following 20 μg of CNP instillation. A sim-
ilar trend of events was also observed in the total BAL cell
count (Figure: 1b), since the overall number of other cell
types like macrophages and lymphocytes where not sig-
nificantly changed upon dose or time response (data not
shown).
Compared to sham exposed mice, only the instillation of
the highest dose (50 μg/mouse) caused a significant
increase in total BAL protein concentration (224.1 ± 29.0
μg/ml versus 114. 4 ± 2.2 μg/ml) 1 day after CNP instilla-
tion, indicating capillary leakage at this concentration i.e.
alveolar barrier injury at this dose (Figure 1c). Time course
investigation of 20 μg instilled lungs however revealed a
significant decrease of BAL protein concentrations from
day 1 (140.0 ± 13.2 μg/ml) to day 3 (99.5 ± 4.8 μg/ml)
and day 7 (89.8 ± 2.2 μg/ml).
Histopathology
Histopathological analysis of the paraffin embedded lung
sections (n = 4) showed a typical dose dependent accumu-
lation of particle laden macrophages and also a time
dependent clearance as reported in many studies. The
degree of accumulation of particle laden macrophages can
be categorized as follows: 5 μg/day 1 (very slight/slight);
20 μg/day 1 (slight/moderate); 50 μg/day 1 (moderate;
focal but marked); 20 μg/day 3 (slight); 20 μg/day 7 (very
slight/slight). In 50 μg/day 1 samples inflammatory cell
infiltration (PMN) was clearly visible whereas at 20 μg/
day 1 slight PMN infiltration was visible.
Molecular analysis for lung and BAL compartment
Marker selection: To select useful molecular markers fol-
lowing CNP i.t instillation from our panel we have
defined a set of criteria based on which they were selected
for further analysis/discussion.
￿ Markers showing a clear dose response following
exposure to CNP (5 μg, 20 μg and 50 μg) in either lung
homogenate and/BAL were only considered. We
defined dose response as a significant increase/
decrease of the expression level of a particular marker
with the ascending CNP dosage compared to the sham
control. Undetectable markers were not considered.
￿ For BAL, markers detected at/above sensitivity level
(see methods) in the pooled samples were only con-
sidered. Markers below sensitivity level were not con-
sidered due to lack of scope of reproducibility inParticle and Fibre Toxicology 2009, 6:31 http://www.particleandfibretoxicology.com/content/6/1/31
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multiple independent samples (n = 4 BAL samples
were pooled/experimental group).
￿ For lung homogenate markers below sensitivity lev-
els were considered as the results were reproducible in
multiple independent samples and were measureable
in all cases (n = 4).
Additional file 1; Table S1 depicts the association of all the
62 markers measured to the explained criteria along with
their respective gene symbol, Entrez identification
number, associated gene ontology terms [GO; Biological
process; according to mouse genome informatics (MGI)
database] and the corresponding sensitivity level for
measurement. Applications of these criteria lead us to
exclude 11 markers from the overall analysis from our
panel of 62 markers from both lung and BAL. The exclu-
sion list from both lung and BAL analysis consists of the
following: APOA1, CD40, Haptoglobin, IgA, IL-17,
SGOT, HO-1, Osteopontin and Myoglobin for not exhib-
iting any response; IL-3 and GST-α being not detectable.
Therefore 51 out of 62 measured proteins have been fur-
ther analyzed in the lung homogenate of which 36 were
above and 15 were below the sensitivity level. We have
analyzed multiple (n = 4) independent lung homogenate
samples which shows a strong homogeneity of the data
within each experimental group and therefore included
the markers below sensitivity level also in our analysis. In
Bronchoalveolar lavage fluid (BAL) cell differentials and protein concentration Figure 1
Bronchoalveolar lavage fluid (BAL) cell differentials and protein concentration. a) Dose dependent influx and time 
dependent resolution of polymorphonuclear leukocytes (PMN) in the BAL following intratracheal (i.t.) instillation of carbon 
nanoparticles (CNP) particles in the C3H/HeJ (C3) mice. (n = 7 animals/experimental group). b) Total cell count in the BAL of 
C3 mice following i.t. instillation of CNP particles. c) Total protein concentration in the BAL of C3 mice showing a dose 
dependent increase and time dependent decrease following i.t instillation of CNP. (**) Significantly different with respect to 
(w.r.t) both sham control and 5 μg exposed; (†) significantly different w.r.t 20 μg exposed at day 1; (††) significantly different 
w.r.t 20 μg at day 1, 5 μg and scham control.
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the pooled BAL samples 21 out of 62 markers were detected
at or above the sensitivity level. All of these 21 BAL mark-
ers exhibited a clear dose response after day 1 with the
highest levels being detected at 50 μg dose in all cases. All
values were compared to sham control samples.
Lung compartment
Response of the protein markers from the lung homoge-
nate are presented as heat map (Figure 2a). We could
detect four distinct categories of response pattern over
time as explained in the following section.
Category 1A
This category consists of 22 markers (Figure 2a). The list
includes: KITL, LIF, IL10, IL5, OSM, CXCL10, IL7, IL1A,
IL12p70, TNFα, CCL12, CCL22, IFNγ, IL11, LCN2, CCL2,
CSF2, IL6, CCL7, CXCL2, TIMP1, and CXCL1 (arranged
serially as in figure 2A). Concentration levels of these
markers at day 7 were significantly decreased compared to
the increased levels detected at 20 μg/day 1 and the levels
reached to basal levels detected in controls. At 20 μg/day
1 concentration levels were significantly elevated com-
pared to controls and/5 μg/day 1. MMP9 and VCAM1
exhibited a significantly increased response only at 50 μg/
day 1 and were therefore not considered for the time
course analysis and not represented in the heatmap.
Category 1B
This category consists of 9 markers (Figure 2A). The list
includes: EGF, F7, CCL19, IL4, FGF9, IL2, F3, CD40L, and
MPO (arranged serially as in figure 2a). Concentration
levels of these markers at day 7 are significantly decreased
compared to the increased levels detected at 20 μg/day 1
but the levels are still higher than the basal levels detected
in control. At 20 μg/day 1 concentration levels were signif-
icantly increased compared to control and/5 μg/day 1.
Category 2A
This category consists of 11 markers (Figure 2a). The list
includes: vWF XCL1, CXCL5, THPO, VEGF, IL1B, IL18,
CSF1, EDN1, CCL3, and CCL4 (arranged serially as in fig-
ure 2A). Concentration levels of these markers at day 7
Heatmap representation of protein concentration levels in lung homogenate and bronchoalveolar lavage (BAL) following intrat- racheal instillation of carbon nanoparticles (CNP) in C3H/HeJ (C3) mice Figure 2
Heatmap representation of protein concentration levels in lung homogenate and bronchoalveolar lavage 
(BAL) following intratracheal instillation of carbon nanoparticles (CNP) in C3H/HeJ (C3) mice. Data shown are 
normalized (highest value is set to "1") for (a) dose and time response for the lung; and (b) dose and time response for the 
BAL, respectively. Red color indicates increasing concentration levels and official protein symbols and the fold inductions for 
each protein at different dose and time are shown. A schematic graphical representation of the markers categorized as cate-
gory 1A, 1B, 2A, and 2B in the lung as calculated by the ratio [percent day 7/day 1] is shown and are explained in the results 
section.
2a. 
2b. Particle and Fibre Toxicology 2009, 6:31 http://www.particleandfibretoxicology.com/content/6/1/31
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remains equivalent to the increased levels detected at 20
μg/day 1. i.e. concentration levels were not significantly
different compared to 20 μg/day 1 and 20 μg/day 3. At 20
μg/day 1 concentration levels were significantly higher
compared to control and/5 μg/24 h.
Category 2B
This category consists of 7 markers (Figure 2a). The list
comprises of: fibrinogen, CRP, APCS, CCL5, CCL9, and
FGF2 (arranged serially as in figure 2a). These markers
exhibit a consistent trend of ascending response at day 7
as calculated by the ratio [percent day 7/day 1] but the
concentrations levels were not significantly different com-
pared to 20 μg/day 1 and/20 μg/day 3. At 20 μg/day 1 con-
centration levels were significantly increased compared to
sham and/5 μg/day 1.
BAL compartment
F3, TNFα, FGF2, IL1B, F7, CCL3, IL18, VEGF, THPO,
CCL4, IL1A, CD40L, CXCL5, CSF2, CXCL2, CSF1, CCL22,
CCL9, CCL2, , CCL7, MMP9 were detected at/above the
sensitivity level and exhibited a clear dose response in the
pooled BAL samples as represented in the heatmap (Fig-
ure 2b). Most of the BAL markers except F3, CD40L, IL1B,
IL18, CCL9 and FGF2 exhibited the expected descending
response pattern with time (i.e similar to category 1A in
lung). CXCL5 exhibited a clear descending response with
time but it was still 1.7 folds higher on day 7 compared to
the sham control (i.e similar to category 1B in lung). CXCL5
was also observed to the most sensitive BAL marker being
the only to be differentially regulated at 5 μg/day 1. It was
upregulated by 1.8 fold at this dose. Highest levels of F3
concentration was detected on day 7 after 20 μg CNP
instillation when PMN influx was resolved (i.e similar to
category 2B in lung). Interestingly CD40L and IL1B concen-
tration levels in the BAL were detected at highest levels on
day 3 after 20 μg CNP instillation in contrast to the other
markers which peaked at day 1 (i.e. delayed response). Con-
centration levels of CCL9, FGF2 and IL-18 remained
equivalently high to day 1 levels also on day 3 following
CNP instillation and were observed to be reduced by day
7 (i.e. extended elevated levels but limited to day 3). It was
interesting to note that several markers were detected at
down regulated (0.6 fold or less) levels on day 7 com-
pared to the sham control. They include: CCL3, CCL4,
CD40L, CXCL2, CSF1, CCL22, CCL9, CCL2, CCL7, and
MMP9. In fact CCL2 and CCL7 were already detected at
markedly down regulated levels already on day 3. MMP9
was detected at 0.6 fold lower compared to sham control
at 5 μg/day 1.
These findings in the lung and BAL compartment indicate
the existence of a complex interacting and regulatory
mechanisms in between these markers which may be dif-
ferent between the lung and BAL compartment and may
also be due to the pleotrophic functional nature of these
proteins.
Time course markers
On this basis when we curated the molecular data in the
lung homogenate and BAL we were able to identify a set
of markers that are sensitive for the acute response at the
day 1 time point, and another set of markers which are
essential even after complete resolution of neutrophil
influx related inflammation (day 7). The later molecular
events can be regarded as plausible protective machinery
in place up to 7 days following exposure to moderately
toxic CNP in a mouse strain with robust lung physiology
as we did not detect any obvious tissue injury/damage.
These time course markers may be considered to have
pathophysiological relevance as they exhibit elevated lev-
els also on day 7 plausibly for maintaining homeostasis.
18 markers represented in categories 2A and 2B in the
lung compartment have been identified to be important
in this context for being detected at elevated levels on day
7. They are as follows: fibrinogen, CRP, APCS, CCL5,
CCL9, FGF2, CCL11, vWF, XCL1, CXCL5, THPO, VEGF,
IL1B, IL18, CSF1, EDN1, CCL3, and CCL4. Individual
response pattern of these markers are represented in figure
(3a-r). We have also identified 6 BAL markers (F3, CD40L,
FGF2, IL1B, IL18 and CCL9) to be important for time
course following 20 μg CNP instillation as they exhibited
a delayed response or extended elevated levels. Although
CD40L and F3 exhibited a significant descending trend at
day 7 in the lung compartment, their levels were quite
high compared to baseline levels. Therefore the expres-
sion trend of these 6 markers in the lung compartment
essentially holds true also in the BAL compartment. How-
ever CSF1, CCL3, CCL4 and VEGF differ in their time
course regulation pattern between BAL compartment and
lung compartment following 20 μg CNP instillation.
These 4 markers remains significantly elevated at day 7 in
the lung whereas they are reduced in the BAL at this time
point.
Biological pathway Analysis
Based on the identification of markers which remained in
elevated concentrations for an extended time period in
lung (at day 7) and BAL (at day 3/day 7) we performed an
extensive literature study which revealed that IL1B and
IL18 act as the central players; and regulation of VEGF via
EDN1 and FGF2 as the ultimate events. This observation
is also illustrated in the pathway analysis (Figure 4) for the
time course response markers from lung and BAL. The
pathway analysis involved the following markers: CCL5,
CCL9, FGF2, CCL11, XCL1, CXCL5, VEGF, IL1B, IL18,
CSF1, EDN1, CCL3, CCL4, F3 and CD40L for homeostatic
and defence responses. We preferred to group the classical
systemic markers fibrinogen, CRP, APCS, THPO and VWFParticle and Fibre Toxicology 2009, 6:31 http://www.particleandfibretoxicology.com/content/6/1/31
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separate in the pathway analysis although several recent
studies show their local origin and role in the lung.
Discussion
It is generally believed that a controlled inflammatory
response is beneficial but it can become detrimental if
dysregulated. Irrespective of the cause, inflammation has
evolved as an adaptive response for restoring homeostasis
[25]. We have previously shown that inhalation of car-
bonaceous nanoparticles causes cellular stress responses
in macrophages and epithelial cells of the lungs within
few hours [26]. There are several reports showing that
inhaled ultrafine particles gain rapid access to the pulmo-
nary epithelial, interstitial and even endothelial layers of
the lung and thus often escape the clearance process of the
respiratory system [27-29]. In this study we aimed to con-
tribute to a better understanding of the molecular mecha-
nism of restoration of lung tissue homeostasis following
CNP challenge while in parallel PMN influx related
inflammation is being resolved. We could show that a
mouse strain with robust lung physiology (C3), when
exposed to a moderately toxic CNP (carbon black,
Printex90) exhibits a dose dependent PMN influx1 day
after instillation (358.24 ± 41.91 × 10E3 PMNs/50 μg).
C3 mice were also able to completely resolve the neu-
trophilic influx (105.53 ± 12.37 × 10E3 PMNs/20 μg/day
1 versus 9.23 ± 3.05 × 10E3 PMNs/sham control ) by the
7th day post instillation of 20 μg CNPs. Besides classical
lung inflammation analysis, we applied a comprehensive
panel of protein markers, primarily representing soluble
proteins involved in cell-cell communication. For our
time course study we have chosen a particle dose of 20 μg,
related to a particle surface area of 54 cm2/mouse which
has been previously shown to cause a significant level of
pulmonary inflammation, characterized by 25% BAL
PMNs in BALB/cJ mice, and which is well below any satu-
ration conditions [12]. Similarly for the C3H/HeJ (C3)
strain used here, the dose-response relationship (response
expressed as BAL PMN cell number) from 5 over 20 to 50
μg CNP revealed a linear shape (R2 = 0, 99).
The "time course" markers (Categories 2A and 2B) have
upon immediate induction after at day 1, been detected at
elevated levels also on day 7 following CNP instillation.
In this context, it is noticeable that protein concentrations
of markers representing processes of tissue homeostasis
Time course response markers (categories 2A and 2B) in the lung homogenate following intratracheal (i.t.) instillation of car- bon nanoparticles (CNP) in C3H/HeJ (C3) mice Figure 3
Time course response markers (categories 2A and 2B) in the lung homogenate following intratracheal (i.t.) 
instillation of carbon nanoparticles (CNP) in C3H/HeJ (C3) mice. (n = 4 animals/experimental group). (a-r) lists the 
markers which showed a typical dose response but remained at elevated levels (not significantly different compared to 20 μg/
day 1) even after day 7 following a significant induction at day 1 due to 20 μg i.t. instillation of CNP. At day 7 neutrophil influx 
related inflammation was completely resolved. Gene symbols are used as shown in additional file 1; Table S1. (**) Significantly 
different with respect to (w.r.t) both scham (Sham) control and 5 μg exposed; (*): Significantly different w.r.t scham control or 
5 μg exposed; (†) significantly different w.r.t 20 μg exposed at day 1; (††) significantly different w.r.t 20 μg at day 1, 5 μg and 
sham control.
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like fibrinogen, CRP, APCS, FGF2, vWF, THPO, VEGF, and
EDN1 (sorted by Category 2B, A criteria, as shown in Fig-
ure 2a and 3 ) are in particular abundant in the inflamma-
tion resolution phase, from day 3 till day 7, where as peak-
concentrations for pro-inflammatory proteins (like
CXCl1, -2, -10, CCL2, -12, -22, IL6, -11 and IFNγ) known
to regulate acute inflammation with leukocyte activation
and recruitment are expectedly detected no later day 1
after CNP instillation. Extensive literature based analysis
of these time course markers revealed astrong association
of IL1B and IL18, suggesting them as the key players; and
VEGF as the main down stream factor controlled through
a EDN1, FGF2 network. This whole set of events seems to
be modulated by a number of other factors also detected
at elevated levels at day 7, namely RANTES (CCL5); MCSF
(CSF1); MIP1α (CCL3); MIP1β (CCL4); MIP1γ (CCL9),
FGF2, Eotaxin (CCL11); GCP2 (CXCL5); IL-18; Lympho-
tactin (XCL1) through a complex regulatory network. In
this context it is important to mention that proteomics
based studies are functionally closer than transcript based
studies. Although our study is proteomics based but is
limited to a finite number of proteins representative of
some pathways. The striking coincidence at day 7 of two
events occurring simultaneously: (i) complete resolution
of inflammation at cellular level along with any evident
tissue damage, and (ii) detection of elevated or even
increased levels of several proteins usually classified as
proinflammatory markers, suggests their differential func-
tion at this later time point more in the direction of their
role in promoting tissue homeostasis. Therefore in the fol-
Pathway analysis of proteins upregulated during time course analysis in lung or bronchoalveolar lavage fluid (BAL) following  intra tracheal instillation of 20 μg carbon nanopaticles (CNP) Figure 4
Pathway analysis of proteins upregulated during time course analysis in lung or bronchoalveolar lavage fluid 
(BAL) following intra tracheal instillation of 20 μg carbon nanopaticles (CNP). At day 7, when complete resolution 
of neutrophilic influx has taken place all of these markers were detected at significantly elevated concentration compared to 
their base line levels following their initial upregulation during the acute response phase (day 1). The predicted molecular net-
work suggest a central role of IL1B (IL: Interleukin) and IL18 in the process. Regulation of vascular endothelial growth factor 
(VEGF) through the endothelin1 (EDN1) and basic fibroblast growth factor (FGF2) network as the end product in the cascade 
to restore homeostasis. Elevated levels of several systemic factors suggest their role locally for maintaining/restoring homeos-
tasis. Gene symbols are used as shown in Additional file 1; Table S1.Particle and Fibre Toxicology 2009, 6:31 http://www.particleandfibretoxicology.com/content/6/1/31
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lowing section we have discussed the possible molecular
cascade which we could associate to tissue homeostasis
and defense response in C3 mice. However we are aware
of the fact that only controlled intervention studies aimed
at revealing mechanistic insights at specific time points
will precisely answer the causation of possible pathologi-
cal situations that may arise due to disruption of this cas-
cade and the fact that our findings are associative at this
point of time.
IL1B and IL18 are the two likely key upstream molecules
Interleukin-1B is a master cytokine, known to be involved
in initiating the innate immune response in vertebrates
[30] and regulation of the expression of several other
cytokines like CCL3, -4, -5, -9 and -11 [31-33]. In vitro,
macrophages exposed to titanium particles release CSF1/
M-CSF through upregulation of IL1B [34]. Treatment of
human endothelial cells with IL1B enhances mRNA
expression of the human CXCL5 homologues [35] and
CXCL5 is also predominantly induced in mesenchymal
cells by IL1B [36]. On a related note we have previously
reported high correlation between the degree of particle
exposure related acute lung inflammation (PMN num-
bers) and IL1B BAL concentrations in mice [12]. In vitro,
macrophages exposed to titanium particles release CSF1/
M-CSF through upregulation of IL1B [34]. Several studies
have shown direct IL1B mediated induction of IL18 and
vice versa [37,38]. IL18 can also induce a number of
cytokines including CCL3 [39], CCL4 [40], CCL5 [41],
CCL11 [42]. Overall, this suggests that IL1B and IL18
together play a crucial role for initiating the immediate
inflammatory response to CNP. CSF1/M-CSF can regulate
IL18 production by human monocytes which in turn may
affect the activation and differentiation of T cells and T-
cell mediated immune response [43]. From these studies
the involvement of IL-1B and IL-18 during the early initi-
ation phase of inflammation up to day 1 is well described,
but less is known for their role in the subsequent resolu-
tion phase. During this time, increased IL-1B levels in the
lung tissue may activate macrophages to clear the battle-
ground such as phagocytosized neutrophis or cellular
debris, as recently suggested by Al-Banna in a model of
bacterial lung infection [44] On a related note a tissue
protective role against bleomycin-induced lung injuries
has also been described for IL-18 [45]. Since the clearance
of inflammatory cells is among the first steps in resolving
the inflammatory responses, the regulation of tissue pro-
tective genes by IL-1 related signalling might rather be
considered for the phase from 3 to 7 days post instillation.
Elevated levels of classical systemic markers
In the current study we detected elevated lung protein lev-
els of CRP, APCS, fibrinogen, factor III (tissue factor), and
VII, vWF, and THPO, even up to day 7. CRP is only mini-
mally induced during inflammation in mice in contrast to
humans[46], whereas serum amyloid P (APCS), the
murine homologue to CRP, is strongly induced following
inflammatory stimuli like endotoxin. However recent
mouse studies failed to detect particle induced hepatic
expression or serum release acute phase markers but
rather suggest a local, pulmonary response upon inhala-
tion [47,26]. Also in an earlier study we showed induced
lung mRNA expression of acute phase proteins (serum
amyloid A3, factor III, and Serpina3n/antitrypsin) upon
inhalation of CNP [26]. Factor III upon interaction with
lung epithelial cells exposed to asbestos particles, has
been suggested to represent a potential mechanism by
which particles might modulate lung remodelling related
epithelial cell responses [48]. During localized injury and
repair the deposition of fibrinogen beta peptide (FGB) in
ECM is discussed as an important cellular response mech-
anism to restore tissue homeostasis and thereby protect-
ing alveolar barrier function [49-51]. Similar implication
might hold true for vWF and THPO, two factors which like
fibrinogen are mainly known for their role during blood
coagulation. Hence this may indicate an enduring tissue
response and suggest the blood coagulation machinery to
be actively engaged.
Crosstalk between defence and homeostatic response 
leading to increased VEGF
As indicated in the schematic pathway model in figure 4,
the proposed "defence pathway", basically represented by
the inflammatory cell activating and attracting cytokines,
CCL3, -4, -5, -9, -11, CXCL5, and XCL1) interacts with the
proposed "homeostatic pathway", represented by VEGF,
FGF2, and EDN1 via other factors (CSF1, CD40L) and
also by the central players IL1B/IL18. Production of VEGF
and FGF2 is reported to be enhanced by IL1B [52]. IL1B
was shown to increase the release of EDN1 by primary
endothelial cells in a dose dependent manner [53] and
EDN1 in turn can regulate IL18 production [54]. IL18
dose dependently increase the production of VEGF [55].
FGF2 and VEGF represent important angiogenic growth
factors within this network. FGF2 acts mainly by mediat-
ing VEGF production. Similar to VEGF, upon CNP instil-
lation FGF2 lung concentrations increased dose
dependently and remained elevated over time. Activated
FGF2 is able to trigger the expression of CSF1 by stromal
cells thus modulating the inflammatory response [56]. In
our study, upon CNP exposure CSF1 remained elevated in
the lung tissue, but declined to basline levels in the lav-
aged compartment (Figure 2). Significant higher levels of
FGF2 have been noted in vascular cells following treat-
ment with EDN1 [57,58] and cell type specific FGF2 tran-
script regulation by EDN1 and IL1B has been reported
[59]. CSF1 can also induce VEGF production by mono-
cytes [60]. Higher levels of VEGF, eventually induced by
pulmonary EDN1 expression, contributes to pulmonary
oedema formation [61] but moderately increased produc-Particle and Fibre Toxicology 2009, 6:31 http://www.particleandfibretoxicology.com/content/6/1/31
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tion of VEGF in the injured lung may also represent a pro-
tective pathway for lung injury recovery and contribute to
the resolution of inflammation [62]. It seems noteworthy
at this point, that we did not detect any evidence for epi-
thelial or alveolar barrier damage upon 20 μg CNP instil-
lation, as indicated by unchanged BAL protein
concentrations (Figure 1c). Thus regardless of the signifi-
cant inflammatory reaction alveolar-capillary barrier
integrity was maintained in C3 mice.
VEGF, FGF2 and EDN1 are mainly involved in processes
like angiogenesis, lung development, blood vessel devel-
opment and cell proliferation. As suggested by our analy-
sis (Figure 4) the cascade ends at VEGF via the FGF2 and
EDN1 network. In the adult lung alterations in VEGF
homeostatsis have been attributed to the pathogenesis of
bronchopulmonary dyplasia, acute lung injury, emphy-
sema and pulmonary arterial hypertension (PAH).
Decreased VEGF levels resulted in the loss of its protective
function on vascular endothelial cells and associated
apoptosis in early acute respiratory distress syndrome
(ARDS) [63,64]. VEGF also facilitates repair following
lung injury by protecting the epithelial surface [65].
Therefore it is critical that an optimal regulation of VEGF
signalling is maintained to protect the lung tissue follow-
ing any inflammatory response. Based on our analysis we
propose that a molecular cascade as represented in figure
4 is active at day 7 post instillation in C3 mice to counter
any tissue disintegrity and to maintain tissue homeostasis.
To conclude, from this study we are able to associate an
orchestrated set of cellular and molecular events triggered
in the lungs of C3 mice with robust lung physiology,
allowing resolution of the acute inflammatory response
with complete abolition of the PMN influx following i.t.
instillation of 20 μg CNP particles to restore the tissue
homeostasis. Pathway and network modeling (Ingenuity
Pathway Analysis) suggests that the major upstream
events in this protective cascade are IL1B and IL18 which
through a complex interaction of several other factors end
up at eleveated VEGF levels via EDN1 and FGF2. Consid-
ering the pleiotrophic functional nature of many of the
chemokines it is interesting to note that elevated levels of
CCL9, CCL3, CCL4, CXCL5, CCL5 and XCL1 at day 7 did
not cause an inflammatory response and thereby indicate
their dual characteristics: in imparting acute inflamma-
tory response (till day 1) and later on possibly in restoring
tissue homeostasis. However in this study relatively
smaller changes in protein concentrations (like 1.5/1.6
folds) although statistically significant warrant careful
interpretation for their biological significance. It needs to
be investigated if mouse strains with unfavorable lung
physiology are able to resolve CNP induced inflammation
through a similar or different mechanism or they suc-
cumb to such a challenge. Modern but elaborate
approaches of mouse genetics, allowing controlled inter-
vention, cell specific and at selected time points will cer-
tainly help to reveal how these factors modulate the entire
process. First of all, comparing mouse strains with a dis-
tinctive capability or kinetic to restore tissue homeostasis
upon CNP induced lung inflammation, should give
important information about the functional contribution
of the here discussed proteins for pro-resolving and/or tis-
sue protective pathways.
Methods
Particles
For CNP instillation Printex 90 particles obtained from
Degussa (Frankfurt, Germany) were used as described ear-
lier [12]. Vials of 5 μg, 20 μg and 50 μg CNP particles were
prepared just before use by suspending in pyrogene-free
distilled water (Braun, Germany). The suspension of par-
ticles was sonicated on ice for 1 min prior to instillation,
using a SonoPlus HD70 (Bachofer, Berlin, Germany) at a
moderate energy of 20 Watt. We favour the use of distilled
water for suspension of particles because the salt content
of phosphate-buffered saline (PBS) causes rapid particle
aggregation comparable to the "salting-out" effect [66]
and thus eliminates consistent instillation conditions.
Zeta potential (33 mV) and intensity weighted median
dynamic light scattering diameter (0.17 μm) were meas-
ured for the printex 90 particles in a pyrogen free distilled
water suspension at a concentration of 20 μg/50 μl using
Zetatrac (Model NPA151— 31A; Particle Metrix GmbH,
Meerbusch, Germany). The particle suspension was pre-
pared under identical conditions used for mouse intra tra-
cheal instillation.
Mouse procedures
Animals
This study was approved by the Bavarian Animal Research
Authority (Reference No: 55.2-1-54-2531-115-05). All the
female C3H/HeJ (C3) animals were purchased from the
Jackson Laboratories (Bar Harbour, ME USA) at the age of
8 weeks at the same time. The animals were housed and
acclimatized at the animal facility of Helmholtz Zentrum
München under specific pathogen free conditions accord-
ing to the Eurpoean Laboratory Animal Science Associa-
tion Guidelines [67] for at least 4 weeks. Food and water
were available ad libitum. The experiments were per-
formed in 12-14 weeks old animals. Experimental groups
were age matched and the age of 12-14 weeks was consid-
ered for this study so as to exclude the effect of any lung
developmental events that may interfere with susceptibil-
ity. By the age of 10 weeks lung development is completed
in mouse and the lung assumes a completely developed,
fully grown and matured structure.
Mice were anesthetized by intraperitoneal injection of a
mixture of xylazine (4.1 mg/kg body weight) and keta-Particle and Fibre Toxicology 2009, 6:31 http://www.particleandfibretoxicology.com/content/6/1/31
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mine (188.3 mg/kg body weight). The animals were then
intubated by a nonsurgical technique [68]. Using a bulb-
headed cannula inserted 10 mm into the trachea, a sus-
pension containing 5, 20, or 50 μg CNP (Printex90)
particles, respectively, in 50 μL pyrogene-free distilled
water was instilled, followed by 100 μL air.
Experimental Design
Seven experimental groups were selected which included
cage control, sham exposed, and CNP exposed (5 μg/day
1, 20 μg/day 1, 20 μg/day 3, 20 μg/day 7, 50 μg/day 1) by
intratracheal (i.t.) instillation. Cage control animals were
not instilled, and sham animals received 50 μL pure dis-
tilled water (vehicle). The animal groups were designed so
as to obtain an acute dose-response relationship [5 μg/day
1, 20 μg/day 1 and 50 μg/day 1] and also to get a time
course response [20 μg/ay1, 20 μg/day 3, 20 μg/day 7] fol-
lowing i.t. instillation. Therefore 5 groups were exposed to
particles and 2 groups served as control (cage control and
sham exposed). Each of the seven experimental groups
consisted of 11 animals. 7 animals were lavaged and tis-
sue samples from 4 mice were collected for protein analy-
sis. 4 non-lavaged animals were used for histopathology.
Lavaged lungs were immediately frozen in liquid nitrogen
following dissection and stored at -80°C until next proce-
dures for molecular analysis. Animals were treated
humanely and with regard for alleviation of suffering.
Bronchoalveolar lavage (BAL) and analysis
On day 1/day 3/day 7 (as per experimental design) after
instillation, mice were anesthetized by intraperitoneal
injection of a mixture of xylazine and ketamine and sacri-
ficed by exsanguination. BAL was performed accordingly
(i.e. day 1/day 3/day 7 after instillation) by cannulating
the trachea and infusing the lungs 10 times with 1.0 mL
PBS without calcium and magnesium, as described previ-
ously [69]. The BAL fluid from lavages 1 and 2 and from
lavages 3-10 were pooled and centrifuged (425 g, 20 min
at room temperature). The cell-free supernatant from lav-
ages 1 and 2 were pooled and used for biochemical meas-
urements such as total protein and panel assays. The cell
pellet was resuspended in 1 mL RPMI 1640 medium (Bio-
Chrome, Berlin, Germany) and supplemented with 10%
fetal calf serum (Seromed, Berlin, Germany); the number
of living cells was determined by the trypan blue exclusion
method. We performed cell differentials on the cytocentri-
fuge preparations (May-Grünwald- Giemsa staining; 2.
200 cells counted). We used the number of polymorpho-
nuclear leukocytes (PMNs) as a marker of inflammation.
Total protein content was determined spectrophotometri-
cally at 620 nm, applying the Bio-Rad Protein Assay Dye
Reagent (no. 500-0006; BioRad, Munich, Germany). We
analyzed 50 μl BAL/mouse to assess panel assays. We have
not observed any statistically significant difference
between cage control and sham exposed control animals
in any of the measurements performed using BAL. There-
fore we have compared all values in comparison to sham
control to avoid redundancy of data.
Histology
4 not lavaged animals per experimental group were used
for histological analysis. Mice were sacrificed by overdose
of Ketamin and the lungs were inflation-fixed at a pressure
of 20 cm H2O by instillation of phosphate buffered 4%
formaldehyde. Three cross slices of the left lobe and slices
of each right lobe (4 lobes) were systematically selected
and embedded in paraffin, and 4 μm thick sections were
stained with hematoxylin and eosin. The sectioned were
then studied by light microscopy.
Protein panel assays
Total lung homogenate was prepared using 50 mM Tris-
HCL with 2 mM EDTA, pH 7.4 as the lysis buffer (1000 μl)
from 4 animals/experimental group. Using the Rodent
MAP™ version 2.0 of the Rules Based Medicine (Austin,
Texas) a panel of mostly proinflammatory and inflamma-
tory markers were analyzed from total lung homogenate
and BAL. The BAL and lung homogenate were always
taken from the same animals to avoid any inter animal
variation. BAL of the 4 animals/group was pooled for the
measurement and only the markers equal to/above (≥)
the sensitivity level were considered. Sensitivity level is the
least detectable dose (LDD) as provided by Rules Based
Medicine. We consider in pooled samples the markers
below sensitivity levels to be not reliable due to lack of
scope for reproducibility in multiple independent sam-
ples. However, in the lung homogenate markers below
LDD were also considered for analysis and discussion as
we could measure samples from 4 independent animals/
group. In all cases a strong homogeneity of data were
observed.
Additionally three more markers hemoxygenase-1 (HO-1;
Stressgen Catalog # 960-071), osteopontin (SPP1; Stress-
gen Catalog # 900-090A) and liopcallin-2 (LCN2; R&D
Systems Catalog # DY1857) were assayed from the same
samples using the respective ELISA kit.
We have not observed any statistically significant differ-
ence between cage control and sham exposed control ani-
mals in any of the measurements performed using BAL
and lung homogenate. Therefore we have compared all
values in comparison to sham control to avoid redun-
dancy of data.
Statistics
A two-way analysis of variance (ANOVA) was used to ana-
lyze differences between control and various exposure
groups. P values less than 0.05 were considered as statisti-
cally significant. All computations were done by the soft-Particle and Fibre Toxicology 2009, 6:31 http://www.particleandfibretoxicology.com/content/6/1/31
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ware packages Statgraphics plus v5.0 (Manugistics,
Rockville, MD) and SAS V9.1 (Cary, NC). Data are pre-
sented as arithmetic mean values of n observations ± the
standard error (SE).
Heatmaps and pathway analysis
Protein expression data from lung tissue (means, n = 4)
and BALF (pools from 4 animals) were used for heatmap
generation. Protein concentrations were normalized to
the highest value for each protein (set to equal 1) and the
resulting values were used as input for heatmap genera-
tion with CARMAweb [70].
Ingenuity software was used to generate interaction net-
works for selected regulated proteins. Only direct interac-
tions between input genes were considered for network
construction.
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